Sudheer Kumar Vuyyuru
@IBDologist
Followers
782
Following
1K
Media
6
Statuses
151
Gastroenterologist, special interest in IBD, IUS, clinical research, Advanced clinical and research fellowship in IBD, University of Western Ontario, Canada.
London, Ontario, Canada
Joined April 2020
Our recent study on ASUC. Colectomy at .Discharge-8%.1 yr-13.5%.3yr -16.1%.5yr- 17.4%.Steroid responders and non-responders have similar outcomes. Day-3 Oxford criteria remain relevant in post biologic era.@vipuljairath @virgisolitano.
academic.oup.com
AbstractBackground and Aims. Outcomes of patients admitted with acute severe ulcerative colitis(ASUC) in the post biologic era are under explored, as well
2
7
30
RT @vipuljairath: Development and external validation of an endoscopic and histologic pouchitis assessment tool: the Atlantic Pouchitis Ind….
pubmed.ncbi.nlm.nih.gov
Development and validation of the API advances pouchitis disease assessment. Integration of endoscopy and histopathology results in an objective, reliable, and responsive instrument to evaluate...
0
11
0
RT @GordonMoranIBD: Available online from today, the latest @BritSocGastro IBD guidelines. Thank you to all who contributed. .
gut.bmj.com
In response to recent advancements in inflammatory bowel disease (IBD) management, the British Society of Gastroenterology (BSG) Clinical Services and Standards Committee (CSSC) has commissioned the...
0
20
0
RT @vipuljairath: An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease.….
pubmed.ncbi.nlm.nih.gov
These recommendations will serve to optimize trial design and facilitate appropriate, acceptable, and standardized RCT corticosteroid handling practices.
0
15
0
RT @vipuljairath: Department of Medicine Residents Research Day. This year we had 95 abstracts from our trainees sharing their research fro….
0
3
0
Excited to share that I’ve completed the IBUS training in intestinal ultrasound for IBD. Grateful to learn this new skill #IBUS.Thanks to Dr.Siwar Albashir, Dr.Prowse at McMasters and @GordonMoranIBD @drgauraang @vipuljairath for encouragement and support @BowelUltrasound
3
0
13
RT @BowelUltrasound: 📢 Join us on Tuesday, May 20th at 1:00 PM CET for another exclusive IBUS SciCom Webinar on "Standardized IUS Scoring i….
0
8
0
Check out our recent comprehensive review on IL23 inhibitors in CD .@vipuljairath @SpringerNature .#IL23p19, #Crohn’s disease #biologics .
pubmed.ncbi.nlm.nih.gov
Interleukin-23 (IL-23), a member of the IL-12 family of cytokines, plays a critical role in intestinal homeostasis and inflammation and is strongly implicated in the pathogenesis of inflammatory...
3
1
7
Glad to share our recently published systematic review and meta analysis on ASUC. @vipuljairath @alimentiv .
pubmed.ncbi.nlm.nih.gov
IFX may be more efficacious than cyclosporine A for the treatment of ASUC. Janus kinase inhibitors are promising treatment options in select individuals. Future studies should explore the efficacy of...
3
3
18
RT @RocioSedanoMD: 💥Our latest on how AI is revolutionizing IBD CTs!💥 AI is boosting patient recruitment, trial efficiency, personalized tt….
journals.sagepub.com
Integrating artificial intelligence (AI) into clinical trials for inflammatory bowel disease (IBD) has potential to be transformative to the field. This article...
0
3
0
RT @marshllj: Tough cases in IBD - spirited discussion from our expert panel. @IBDMD @SeowCynthia @MatthieuAllez @vipuljairath @guthealthmd….
0
4
0
RT @Bealoquebea: How often during a colonoscopy in a patient w #CD could we have missed lesions that would have led to a change in therapy?….
0
27
0
RT @UEGJournal: New in UEG Journal . 🆕 Prevalence of Complications in IBD Detected by Cross-Sectional Imaging. ✴️ 33.2% stricturing compli….
0
7
0
RT @BowelUltrasound: The first #IBUS Regional Hybrid Module 1 Workshop in London was a great success. Thank you to all participants and fac….
0
5
0
Glad to share first stem cell study in Perianal CD from India @aiims_newdelhi . 4yr of great team effort led by Prof Vineet Ahuja. MSCs are effective and safe . Valuable Tx for PFCD with limited options.Proud to be part of the team.@BhaskarK_Dr @DrPeeyushK.
link.springer.com
Background Perianal fistulas (PF) affect one-third patients with Crohn’s disease (CD) with limited therapeutic options. There is dearth of literature on safety and efficacy of bone marrow-derived...
6
6
46